ir.editasmedicine.com Open in urlscan Pro
2a02:26f0:3500:18::1724:a29d  Public Scan

Form analysis
0 forms found in the DOM

Text Content

Skip to main navigation
 * Newsroom
 * Get in Touch
 * LinkedIn

 * Research and Pipeline
 * CRISPR Gene Editing
 * For Patients
 * Who We Are
 * Join Our Team
 * Investors

 * Newsroom
 * Get in Touch
 * LinkedIn




MEDIA & INVESTORS

 * Overview
 * Press Releases
 * Events & Presentations
 * Corporate Governance
   * Documents & Charters
   * Management
   * Board of Directors
   * Committee Composition
   * Annual Meeting Materials
 * Financials & Filings
   * SEC Filings
   * Annual Reports
 * Stock Information
   * Stock Quote & Chart
 * Investor FAQs
 * Contact


INVESTORS


OVERVIEW


STOCK QUOTE

NASDAQ: EDIT
$5.62
Change-0.27 (-4.58%) Volume1,739,797 52 Week High$11.91 52 Week Low$4.91 May 17,
2024 4:00 PM EDT

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events
Stifel’s 2nd Annual Genetic Medicines Forum
May 28, 2024
Add to Outlook
Add to Google Calendar
Location
Virtual


Recent News
May 14, 2024
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of
Reni-cel at the European Hematology Association 2024 Congress in June

May 10, 2024
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing
Medicine Technologies at the American Society of Gene and Cell Therapy Annual
Meeting

May 8, 2024
Editas Medicine Announces First Quarter 2024 Results and Business Updates





>> PRESS RELEASE SEE ALL

 * See all


SIGN UP FOR E-MAIL ALERTS

Sign Up

FOR INVESTORS:

Cristi Barnett
Editas Medicine, Inc.
Phone: 617.401.0113
E-mail: ir@editasmed.com

FOR MEDIA:

Cristi Barnett
Editas Medicine, Inc.
Phone: 617.401.0113
E-mail: cristi.barnett@editasmed.com





>> MAIN NAVIGATION

 * Research and Pipeline
 * CRISPR Gene Editing
 * For Patients
 * Who We Are
 * Join Our Team
 * Investors



--------------------------------------------------------------------------------

©Copyright 2024 Editas Medicine


>> FOOTER MENU

 * Get in Touch
 * Investors
 * Privacy Policy
 * Terms of Use